Advantages concerning therapy with angiotensin II receptor 1 blockers in patients with arterial hypertension and chronic nephropathy

Abstract

Angiotensin II receptor 1 blockers named sartans, among other antihypertensive drugs, poses a special nephroprotective properties. Both sartans and inhibitors of angiotensin converting enzyme improves glomerular hemodynamics and present a variety of beneficial nonhemodynamic effects that decreasing proteinuria and slowing glomerular fibrosis. In several prospective, randomized trials, it was shown that sartans slow the progression of diabetic nephropathy. It can be also presumed that sartans exert similar effects in patients with nondiabetic chronic nephropathy. However clinical trials with limited number of patients with chronic nephropathy were disable to prove, whether obtained nephroprotection effect is followed by the improvement of patients survival.